|
End-of-day quote
Korea S.E.
2026-09-10
|
5-day change | 1st Jan Change | ||
| 53,100.00 KRW | -1.30% |
|
-5.68% | -55.75% |
| 08-22 | Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate | CI |
| 07-15 | Alert wrongly tagged to Orum Therapeutics withdrawn | RE |
Company Valuation: Orum Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 |
|---|---|
| Market Cap 1 | 2,547,884 |
| Change | - |
| Enterprise Value (EV) 1 | 2,440,781 |
| Change | - |
| P/E | -59.5x |
| PBR | 19.5x |
| PEG | -0x |
| Capitalization / Revenue | 108,125x |
| EV / Revenue | 103,580x |
| EV / EBITDA | -50.4x |
| EV / EBIT | -47.2x |
| EV / FCF | - |
| FCF Yield | - |
| Dividend per Share 2 | - |
| Rate of return | - |
| EPS 2 | -2,017 |
| Distribution rate | - |
| Net sales 1 | 23.56 |
| EBITDA 1 | -48,462 |
| EBIT 1 | -51,759 |
| Net income 1 | -41,969 |
| Net Debt 1 | -107,103 |
| Reference price 2 | 120,000.00 |
| Nbr of stocks (in thousands) | 21,232 |
| Announcement Date | 3/19/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 872M | |
| 20.12x | 7.11x | 14.28x | 1.48% | 68.52B | |
| 32.41x | 9.38x | 45.24x | 0.04% | 62.88B | |
| -78.84x | 15.22x | -73.41x | -.--% | 28.13B | |
| 29.47x | 6.3x | 16.34x | -.--% | 25.56B | |
| -14.82x | 5.45x | -6.85x | -.--% | 24.65B | |
| 26.99x | 5.06x | 16.84x | -.--% | 19.81B | |
| 50.73x | 18.74x | 38.02x | 0.3% | 17.69B | |
| 1267.09x | 36.54x | 797.35x | -.--% | 14.66B | |
| 18.02x | 5.37x | 12.54x | -.--% | 14.45B | |
| Average | 150.13x | 12.13x | 95.59x | 0.2% | 27.72B | |
| Weighted average by Cap. | 79.09x | 10.30x | 53.86x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A475830 Stock
- Valuation Orum Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
